An updated Review on Therapeutic Potential of Entrectinib as a Promising TrK, ROS 1, and ALK Inhibitor in Solid Tumors and Lung Cancer
M. Archana, Mariya Palathingal, K. Athulya Damodharan, P. Ashisha, Nuaman, Akash Marathakam
Journal of Pharmaceutical Research International · pp. 413–421 · Published 20 Sep 2021
10.9734/jpri/2021/v33i44A32633Abstract
Entrectinib is a selective inhibitor of tyrosine kinases , tropomyosin receptor kinases that targets oncogenic rearrangements in Neurotropic Tyrosine Receptor kinase, c-ros oncogene 1 and Anaplastic lymphoma kinase used for the treatment of various solid tumors. Entrectinib gained its first worldwide approval in Japan in June 2019 for the treatment of NTRK fusion-positive, advanced or recurring solid tumours in adults and children. In august 15, 2019 drug got FDA approval for the treatment of solid tumors in adult and children aged 12 and above. This article summarizes current status of Entrectinib from ongoing clinical trails and ideal place for drug in therapy.
Cited by 1
Laura Veronica Budău, Cristina Pop, Cristina Mogoșan · Pharmaceuticals · 2025
Related research
- Viscothionin Suppresses Human Non-small Cell Lung Cancer via Inhibiting the STAT3 Signaling Pathway — shares topic coverage
- Beyond Palliation: Redefining the Surgical Frontier in Stage IV Non-Small Cell Lung Cancer — shares topic coverage
- Biomarker: A Potential Novel Therapeutic Target for Early Detection of Lung Cancer — shares topic coverage
- Ciliary Body Metastasis Treated with Radiotherapy Alone in a Case of Lung Adenocarcinoma: A Case Report — shares topic coverage
- Exosomal Communication in the Tumour Microenvironment of Non-small Cell Lung Cancer: Implications for Progression and Therapy — shares topic coverage
Article metrics
Real usage data collected on this platform.
0
Page views
0
PDF downloads
0
Outbound clicks
1
Citations
Views by country
Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".
No views recorded yet.
Traffic sources
Referring site, by host.
No traffic recorded yet.
Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.